CareLit · DOI-Nachweis · Pneumologie
DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC)
DOI 10.1055/s-0033-1334708
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ von Pawel, V Gorbounova, M Reck, DM Kowalski, A Allard, M Chadjaa, A Rey, J Bennouna, F Grossi
ZeitschriftPneumologie
Ausgabe02/2013
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Ombrabulin is a vascular disrupting agent and analogue of combretastatin A4 that damages established tumor vasculature, which causes tumor necrosis and regression. DISRUPT (NCT01263886) evaluated whether adding ombrabulin to a taxane-platinum doublet in the 1st-line setting improves outcomes in patients with metastatic NSCLC. Methods: Patients (≥18yrs, ECOG 0 – 1, stage IV) were randomized 1:1 to ombra…
Zitieren
Zitierempfehlung
J von Pawel, V Gorbounova, M Reck, DM Kowalski, A Allard, M Chadjaa, A Rey, J Bennouna, F Grossi (2013) DISRUPT: A randomized phase 2 trial of ombrabulin (AVE8062) combined with a taxane-platinum regimen in the first-line treatment of metastatic non-small cell lung cancer (NSCLC). Pneumologie (02). https://doi.org/10.1055/s-0033-1334708
Mit CareLit weiterarbeiten